Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 2/2015

01-04-2015 | Research

Immunophenotype and Human Papillomavirus Status of Serous Adenocarcinoma of the Uterine Cervix

Authors: Shinichi Togami, Yuko Sasajima, Takahiro Kasamatsu, Rie Oda-Otomo, Satoshi Okada, Mitsuya Ishikawa, Shun-ichi Ikeda, Tomoyasu Kato, Hitoshi Tsuda

Published in: Pathology & Oncology Research | Issue 2/2015

Login to get access

Abstract

Serous adenocarcinoma of the cervix (SACC) is a very rare tumor. Our study aimed to characterize the immune profile and human papillomavirus (HPV) status of SACC, in comparison with other serous adenocarcinomas arising in the female genital tract. The pathological specimens obtained from 81 patients with serous carcinoma of the uterine cervix (n = 12), 29 endometrium, 20 ovary and 20 patients with mucinous carcinoma of the uterine cervix were reviewed. We assessed the expression of WT-1, p53, p16, HER2, CEA, and CA125 by immunohistochemistry and HPV DNA by PCR in 12 SACC samples. Their immune profile was compared with that of uterine papillary serous carcinoma (UPSC), ovarian serous adenocarcinoma (OSA), and mucinous endocervical adenocarcinoma (MEA). WT-1 and HER2 were expressed in very few SACC samples (0 and 0 %, respectively), but p16, CA125, CEA and p53 were present in 100, 92, 58 and 50 %, respectively. The difference in WT-1 expression between SACC and UPSC, MEA is not significant, but SACC differ significantly from OSA (p < 0.01). HPV DNA (type 16 or 18) was detected in 4 of the 12 SACC. The immunophenotype of SACC was similar to UPSC, whereas the frequency of expression of WT-1 was significantly lower in SACC than OSA. It appeared that p53 expression was associated with worse clinical outcome in patients with SACC, and that HPV infection was related to its occurrence.
Literature
1.
Olawaiye AB, Rauh-Hain JA, Withiam-Leitch M, Rueda B, Goodman A, del Carmen MG (2008) Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. Gynecol Oncol 110(3):293–298CrossRefPubMed
2.
Zhou C, Gilks CB, Hayes M, Clement PB (1998) Papillary serous carcinoma of the uterine cervix: a clinicopathologic study of 17 cases. Am J Surg Pathol 22(1):113–120CrossRefPubMed
3.
Togami S, Kasamatsu T, Sasajima Y, Onda T, Ishikawa M, Ikeda SI, Kato T (2012) Tsuda H serous adenocarcinoma of the uterine cervix: a clinicopathological study of 12 cases and a review of the literature. Gynecol Obstet Investig 73(1):26–31CrossRef
4.
Bocker W (2002) WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics. Verh Dtsch Ges Pathol 86:116–119PubMed
5.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131(1):18–43PubMed
6.
de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ (1995) The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 76(Pt 4):1057–1062CrossRefPubMed
7.
Baalbergen A, Ewing-Graham PC, Eijkemans MJ, Helmerhorst TJ (2007) Prognosis of adenocarcinoma of the uterine cervix: p53 expression correlates with higher incidence of mortality. Int J Cancer 121(1):106–110CrossRefPubMed
8.
9.
Tsuda H, Jiko K, Tsugane S, Yajima M, Yamada T, Tanemura K, Tsunematsu R, Ohmi K, Sonoda T, Hirohashi S (1995) Prognostic value of p53 protein accumulation in cancer cell nuclei in adenocarcinoma of the uterine cervix. Jpn J Cancer Res 86(11):1049–1053CrossRefPubMed
10.
Batistatou A, Zolota V, Tzoracoleftherakis E, Scopa CD (2000) Papillary serous adenocarcinoma of the endocervix: a rare neoplasm. Immunohistochemical profile. Int J Gynecol Cancer 10(4):336–339CrossRefPubMed
11.
Nofech-Mozes S, Rasty G, Ismiil N, Covens A, Khalifa MA (2006) Immunohistochemical characterization of endocervical papillary serous carcinoma. Int J Gynecol Cancer 16(Suppl 1):286–292CrossRefPubMed
12.
Broker TR, Jin G, Croom-Rivers A, Bragg SM, Richardson M, Chow LT, Vermund SH, Alvarez RD, Pappas PG, Squires KE, Hoesley CJ (2001) Viral latency–the papillomavirus model. Dev Biol 106:443–51, discussion 452–3, 465–475
13.
Fontaine J, Hankins C, Mayrand MH, Lefevre J, Money D, Gagnon S, Rachlis A, Pourreaux K, Ferenczy A, Coutlee F (2005) High levels of HPV-16 DNA are associated with high-grade cervical lesions in women at risk or infected with HIV. AIDS (London, England) 19(8):785–794CrossRef
14.
Riethdorf L, Riethdorf S, Lee KR, Cviko A, Loning T, Crum CP (2002) Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia. Hum Pathol 33(9):899–904CrossRefPubMed
15.
Swan DC, Tucker RA, Tortolero-Luna G, Mitchell MF, Wideroff L, Unger ER, Nisenbaum RA, Reeves WC, Icenogle JP (1999) Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol 37(4):1030–1034PubMedCentralPubMed
16.
Andersson S, Rylander E, Larsson B, Strand A, Silfversvard C, Wilander E (2001) The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer 37(2):246–250CrossRefPubMed
17.
Missaoui N, Hmissa S, Frappart L, Trabelsi A, Ben Abdelkader A, Traore C, Mokni M, Yaacoubi MT, Korbi S (2006) p16INK4A overexpression and HPV infection in uterine cervix adenocarcinoma. Virchows Arch 448(5):597–603CrossRefPubMed
18.
Pirog EC, Kleter B, Olgac S, Bobkiewicz P, Lindeman J, Quint WG, Richart RM, Isacson C (2000) Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol 157(4):1055–1062CrossRefPubMedCentralPubMed
19.
Chiesa-Vottero AG, Malpica A, Deavers MT, Broaddus R, Nuovo GJ, Silva EG (2007) Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol 26(3):328–333CrossRefPubMed
20.
Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S (2003) Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88(1):63–73CrossRefPubMedCentralPubMed
21.
Franco EL, Rohan TE, Villa LL (1999) Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 91(6):506–511CrossRefPubMed
22.
Nofech-Mozes S, Khalifa MM, Ismiil N, Dube V, Saad RS, Sun P, Seth A (2010) Ghorab Z Detection of HPV-DNA by a PCR-based method in formalin-fixed, paraffin-embedded tissue from rare endocervical carcinoma types. Appl Immunohistochem Mol Morphol 18(1):80–85CrossRefPubMed
23.
Hadzisejdc I, Krasevic M, Haller H, Grahovac B (2007) Distribution of human papillomavirus types in different histological subtypes of cervical adenocarcinoma. Coll Anthropol 31(Suppl 2):97–102
24.
Acs G, Pasha T, Zhang PJ (2004) WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 23(2):110–118CrossRefPubMed
25.
Hashi A, Yuminamochi T, Murata S, Iwamoto H, Honda T, Hoshi K (2003) Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Int J Gynecol Pathol 22(4):374–377CrossRefPubMed
26.
Hylander B, Repasky E, Shrikant P, Intengan M, Beck A, Driscoll D, Singhal P, Lele S, Odunsi K (2006) Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Gynecol Oncol 101(1):12–17CrossRefPubMed
27.
Lin X, Lindner JL, Silverman JF, Liu Y (2008) Intestinal type and endocervical-like ovarian mucinous neoplasms are immunophenotypically distinct entities. Appl Immunohistochem Mol Morphol 16(5):453–458CrossRefPubMed
28.
Nofech-Mozes S, Khalifa MA, Ismiil N, Saad RS, Hanna WM, Covens A, Ghorab Z (2008) Immunophenotyping of serous carcinoma of the female genital tract. Mod Pathol 21(9):1147–1155CrossRefPubMed
29.
Deavers MT, Malpica A, Silva EG (2003) Immunohistochemistry in gynecological pathology. Int J Gynecol Cancer 13(5):567–579CrossRefPubMed
30.
Alkushi A, Irving J, Hsu F, Dupuis B, Liu CL, Rijn M, Gilks CB (2003) Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch 442(3):271–277PubMed
31.
Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S (2005) Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 104(7):1391–1397CrossRefPubMed
32.
Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH (2004) Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 22(15):3126–3132CrossRefPubMed
33.
Togami S, Sasajima Y, Oi T, Ishikawa M, Onda T, Ikeda S, Kato T, Tsuda H, Kasamatsu T (2012) Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma. Cancer Sci 103(5):926–932CrossRefPubMed
Metadata
Title
Immunophenotype and Human Papillomavirus Status of Serous Adenocarcinoma of the Uterine Cervix
Authors
Shinichi Togami
Yuko Sasajima
Takahiro Kasamatsu
Rie Oda-Otomo
Satoshi Okada
Mitsuya Ishikawa
Shun-ichi Ikeda
Tomoyasu Kato
Hitoshi Tsuda
Publication date
01-04-2015
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2015
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-014-9854-y

Other articles of this Issue 2/2015

Pathology & Oncology Research 2/2015 Go to the issue

Research

A Chinese herbal Formula, Chang-Wei-Qin, Synergistically Enhances Antitumor Effect of Oxaliplatin

Research

Lantana camara Induces Apoptosis by Bcl-2 Family and Caspases Activation

Research

Overexpression of Autophagy-Related 16-Like 1 in Patients with Oral Squamous Cell Carcinoma

Letter to Editor

Pericardial Tamponade Caused by Tumor Hemorrhage – a Rare Complication of Metastatic Testicular Choriocarcinoma

Research

Changes of KRAS Exon 2 Codon 12/13 Mutation Status in Recurrent Colorectal Cancer

Research

Prognostic Value of Ki-67 in Breast Carcinoma: Tissue Microarray Method Versus Whole Section Analysis- Potentials and Pitfalls
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits